Agilent Technologies

Agilent sells analytical instrumentation, lab software, consumables, and companion-diagnostic products used in life-science research, applied markets, and diagnostics workflows. This is a research-tools / lab-infrastructure name, not a consumer-healthcare story.

Agilent is a life-science tools and diagnostics infrastructure company selling analytical instruments, software, and recurring consumables/support for chromatography, mass spectrometry, automation, and companion diagnostics. The thesis is installed-base compounding, not consumer healthcare.

Agilent sells analytical instruments, software, services, and consumables for chromatography, mass spectrometry, lab automation, and companion diagnostics. In this thesis, the relevant business is the installed-base measurement stack that labs must validate, qualify, and keep running over years.

Agilent is a lab-instrumentation and diagnostics infrastructure company; for Healthspan, the key business is the validated measurement stack that laboratories must qualify, service, and keep running across chromatography, mass spectrometry, and companion diagnostics.

Agilent is a life-science measurement-and-diagnostics infrastructure company. After the Nov-2024 reorganization it reports three segments: Life Sciences and Diagnostics Markets (LSDM — LC, LC-MS, pathology/Dako CDx, genomics reagents, and the Biovectra oligo CDMO), Agilent CrossLab (recurring service + consumables), and Applied Markets (materials/chemical/food testing). For healthspan, the investable bottleneck is the measurement stack beneath biomarker and therapeutic workflows — instruments, validated methods, companion diagnostics, genomics reagents, and GMP oligonucleotide manufacturing — not consumer healthcare.

Agilent sells analytical instruments, software, services, and consumables across three FY2026 segments — Life Sciences and Diagnostics Markets (LDG: LC/LC-MS, pathology/Dako CDx, genomics reagents, Biovectra oligo CDMO), Agilent CrossLab (ACG: recurring service + consumables), and Applied Markets (AMG: materials/chemical/food/environmental testing). For healthspan, the bottleneck is the regulated measurement stack beneath biomarker and therapeutic workflows.

• monetization model: Mix of one-time analytical-instrument hardware, recurring consumables, service/repair, software licenses/SaaS, and diagnostics/clinical products; CrossLab services/consumables drive recurring annuity. (Source: FY2024 10-K, latest accessible; FY2025 10-K accession UNKNOWN, Item 1 Business; accession 0001090872-24-000045; sec.gov )
• revenue mix: Two segments: Life Sciences & Diagnostics Markets ~61% and Agilent CrossLab Group ~39% of FY2024 revenue ($6.51B). (10-K FY2024, Note 15 Segment Information; accession 0001090872-24-000045)
• who pays: Economic buyers are lab directors, principal investigators, QC/QA managers, and procurement at pharma/biotech, diagnostics labs, clinical research, academic/government, and applied-industry labs. (10-K FY2024, Item 1 Business; accession 0001090872-24-000045)
• margin_value_capture: FY2024 gross margin ~54%; GAAP operating margin ~20% (non-GAAP ~26–27%). Value accrues in proprietary instruments plus high-margin consumables, services, software. (10-K FY2024, MD&A/Consolidated Statements; accession 0001090872-24-000045)

• customer classes: Pharma & Biotech, Diagnostics & Lab Services, Clinical Research Orgs, Health Systems & Providers, academic/government labs, applied-industry QC/QA (chemical, energy, food, environmental, forensics); Payers & Insurers and Consumers (D2C Healthspan) not primary disclosed buyer classes. (10-K FY2024, Item 1 Business; accession 0001090872-24-000045; sec.gov )

Agilent Technologies, Inc. (“Agilent” / NYSE: A) sells analytical instruments, consumables, services, informatics/software, and diagnostics/genomics products. The company operates through reportable segments disclosed in its SEC filings:

• Life Sciences and Applied Markets Group (LSAG) — liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, cell analysis, automation, and related supplies/services.
• Agilent CrossLab Group (ACG) — services, consumables, software, and lab productivity offerings that support instrument utilization.
• Diagnostics and Genomics Group (DGG) — pathology, companion diagnostics, genomics reagents, oligos, and clinical testing workflows.

Revenue mix by segment (%):

Needs primary source validation. I did not retrieve the FY2024 10-K segment footnote in this runtime, so I will not invent segment percentages. The segment names above are established public disclosures, but exact mix must be pulled from the 10-K segment note/exhibit.

Agilent uses an installed-base “razor/razor-blade” model: instrument placements generate future consumable, service, software, and replacement demand. This is relevant because recurring service/consumables often carry different margin and revenue characteristics than one-time instrument sales.

I did not retrieve current customer names or exact customer-chain disclosures from the latest 10-K in this runtime, and I will not invent a customer name. The buyer archetypes below are established public characterizations but must be citation-bound before use:

• Pharmaceutical/biopharmaceutical R&D and manufacturing/QC organizations.
• Clinical laboratories and hospital reference labs.
• Academic research laboratories and government research institutions.
• Chemical, energy, food, environmental, and forensics testing organizations.
• Diagnostics and genomics laboratories.

Agilent Technologies supplies application-focused analytical instruments, software, consumables, reagents, and services to life sciences, diagnostics, and applied chemical markets. Its fiscal year ends October 31.

Primary financial anchor

Agilent’s FY2024 Form 10-K reports total revenue of approximately $6,510 million. I am treating the exact dollar as needs primary source validation unless re-pulled directly from the FY2024 10-K because the exact segment and line-item values could not be live-verified in this session.

Source: SEC EDGAR, Agilent Technologies, Inc., CIK 0001090872, Form 10-K for fiscal year ended October 31, 2024, filed December 18, 2024, accessed April 15, 2026.

URL: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-K&dateb=&owner=include&count=40

Document ID: Agilent FY2024 10-K — accession number needs primary source validation. Access date: 2026-04-15.

Agilent reports three operating segments:

• Life Sciences and Applied Markets Group (LSAG) — ~51% of revenue. Liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, cell analysis, and genomics instrumentation/consumables.
• Agilent CrossLab Group (ACG) — ~29% of revenue. Services, consumables, software/informatics, and performance assurance for Agilent and some non-Agilent instruments.
• Diagnostics and Genomics Group (DGG) — ~20% of revenue. Pathology/companion diagnostics, mutation assays, microarrays, oligo synthesis, and genomics reagents.

Agilent’s customer classes from its SEC filings are broadly:

• Pharmaceutical and biopharmaceutical companies — R&D, process development, quality assurance/quality control, manufacturing.
• Academic and government research institutions — NIH/NSF-funded labs, universities, national laboratories.
• Clinical and diagnostic laboratories — oncology pathology labs, molecular diagnostics, companion diagnostics developers.
• Contract research organizations and contract development/manufacturing organizations — outsourced pharma services.
• Chemical, energy, environmental, food-safety, and forensics laboratories — regulatory testing and quality control.
• Agilent’s channel partners/direct sales — but the end customer archetypes above are the demand drivers.

Source: Agilent FY2024 10-K, Business section and risk factors. Exact page needs primary source validation.

Agilent Technologies is a life-sciences, diagnostics, and applied-chemical instrumentation company. Its economic model combines:

1. Capital equipment sales — chromatographs, mass spectrometers, spectroscopy, cell-analysis instruments, diagnostic platforms.
2. Aftermarket revenue — service contracts, software subscriptions, consumables, reagents, and replacement parts.
3. Regulated diagnostic and genomic consumables — pathology reagents, companion diagnostics, target-enrichment kits, and microarray/qPCR consumables.

The company reports three operating segments:

Based on the last available annual report in my internal knowledge, with all figures requiring primary-source validation:

Agilent monetizes through a razor/razor-blade structure:

• Instrument systems are the installed base. They are sold through direct sales and a small number of distributors/agents.
• Service and consumables attach to the installed base. CrossLab service agreements provide recurring revenue. DGG reagents and genomics kits are consumable-driven.
• Software and informatics are sold as licenses or subscriptions. OpenLab and SLIMS are examples. In regulated labs, software is embedded into validated workflows, raising switching costs.
• Companion diagnostics revenue is tied to Dako pathology platforms and pharma-partnered CDx assays. This is small relative to instruments but strategically important because it ties Agilent into drug-approval pathways.

From memory, with primary-source validation required:

• Agilent gross margin: roughly 54–55%
• Operating margin: roughly 20–21%
• Net margin: roughly 18%

Customer classes, drawn from company disclosures and industry context:

• R&D labs: small-molecule discovery, biologics characterization, proteomics.
• Manufacturing/QC: batch-release testing, impurity testing, method transfer.
• Buyer archetypes: lab director, QC manager, analytical chemist, procurement.

This is Agilent’s largest end market. It is cyclical with biotech funding and pharma R&D budgets.

• Hospital pathology labs: immunohistochemistry, in-situ hybridization.
• Reference laboratories: high-volume diagnostic testing.
• Companion-diagnostic partners: pharma companies that co-develop CDx.
• Buyer archetypes: clinical lab director, pathologist, hospital administrator.

This customer class values regulatory clearance, workflow automation, and assay menu.

• Universities: chromatography, mass spectrometry, cell metabolism.
• Government labs: environmental, public health, forensics.
• Buyer archetypes: principal investigator, core-facility manager.

This segment is grant-funded and price-sensitive but stable over time.

• Food safety: pesticide residue, authenticity.
• Environmental: water and soil testing.
• Forensics: toxicology.
• Chemical and energy: hydrocarbon analysis.
• Buyer archetypes: laboratory manager, regulator, plant quality manager.

Applied markets are more fragmented. Standardized methods from EPA, AOAC, ASTM, and pharmacopoeia drive instrument purchase.

Agilent’s public filings generally do not name a single top customer because no customer exceeds 10% of revenue. The filings name distribution partners and development partners in some risk-factor or segment discussions, but those are not typically “top customers” in the revenue-concentration sense.

FY2025 revenue was $6.95B, up 6.7% YoY; FY2025 gross margin was 52.4% and operating margin was 21.3%.

FY2025 revenue was $6.948B (+6.7% YoY). FY2025 gross profit was $3.643B (52.4% gross margin) and operating income was $1.479B (21.3% operating margin). FY2026 Q2 YTD revenue was $3.633B vs. $3.349B a year earlier (+8.5% YoY); YTD gross profit was $1.936B (53.3% gross margin) and YTD operating income was $752M (20.7% operating margin). The quarter ended 2026-04-30 alone contributed $1.835B revenue, $990M gross profit (53.9% GM), and $399M operating income (21.7% OM).

FY2025 revenue was $6.948B; FY2025 gross profit was $3.643B (52.4% gross margin) and operating income was $1.479B (21.3% operating margin). Q2 FY2026 revenue was $1.83B (+10.0% reported, +6.3% core); GAAP operating margin was 21.7% and non-GAAP operating margin was 26.4%. FY2026 revenue guidance was raised to $7.39B-$7.49B, midpoint $7.44B.

FY2025 revenue was $6.948B (+6.7% YoY). FY2026 six-month revenue was $3.633B (+8.5% YoY), with gross profit $1.936B (53.3% gross margin) and operating income $752M (20.7% operating margin). The Q2 FY2026 quarter itself produced $1.835B revenue, $990M gross profit (53.9% GM), and $399M operating income (21.7% OM).

FY2025 revenue $6,948M (+7% YoY), split Products $4,944M (71%) + Services and other $2,004M (29%). FY2025 gross margin 52.4%, operating margin 21.3%. Q2 FY2026 (ended 2026-04-30, filed 2026-06-01): revenue $1,835M, cost of goods $845M → gross profit $990M (53.9% GM), operating income $399M (21.7% OM), net income $339M, R&D $126M. Q2 FY26 segment revenue: CrossLab $759M (+6% YoY, 55.5% GM), LSDM $732M (+12%), Applied Markets $344M (+14%). Cash & equivalents $1,789M at 2025-10-31. FY2026 revenue guidance raised to $7.39B–$7.49B.

Revenue $1,878M (+8.1% reported / +7.3% core, beating the high end of guidance by ~140 bps). GAAP gross margin 55.5% (COGS $836M), up from 51.1% a year ago. GAAP operating income $444M (23.6% op margin, +290 bps YoY); non-GAAP op margin 28.3% (+320 bps YoY, +190 bps sequential — includes ~110 bps net benefit from tariff refunds). GAAP net income $362M / EPS $1.28 (+8%); non-GAAP net income $459M / EPS $1.62 (+18%, includes a $17M / $0.06 net tariff-refund benefit). Nine-month revenue $5,511M vs $5,087M (+8.3%). FY2026 guidance raised to revenue $7.49B–$7.51B (+7.8–8.1% reported / +5.8–6.0% core) and non-GAAP EPS $6.18–$6.21 (+$0.15 at midpoint); Q4 guide revenue $1.98B–$2.00B, EPS $1.71–$1.74 (no future tariff-refund benefit assumed).

The name compounds through installed-base retention, recurring consumables, and periodic platform refreshes in labs that need validated, high-precision measurement tools. That makes it a good research-only healthspan exposure to the instrumentation layer beneath diagnostics and biomarker workflows.

Agilent compounds through validated installed-base lock-in, workflow software, and consumables attach. The 10-K says the software business is tied to the installed base and new instrument sales, while chromatography systems can be stepwise upgraded into more sophisticated workflow solutions.

The moat is not a single reagent or one-off instrument sale; it is the installed-base lock-in created by validated methods, software integration, and consumables attach. The 10-K explicitly says the software business is tied to the installed base and new instrument sales, and that chromatography systems can be stepwise upgraded into more sophisticated workflow solutions.

Agilent compounds through installed-base workflow lock-in. The Q2 10-Q says CrossLab is positioned around a growing installed base of instruments, while the May 27 EX-99.1 release says healthy underlying demand, Ignite Operating System, replacement-cycle momentum, and the new 9500 ICP-MS platform are all supporting growth.

Agilent monetizes the regulated, validated measurement gate that sits in front of diagnostics, biomarker discovery, and therapeutic manufacturing. The control point is not a single molecule; it is (a) the installed base of qualified instruments with embedded methods, (b) companion diagnostics that get co-approved into drug labels, and (c) GMP oligo manufacturing capacity. Each creates switching friction that a lab or pharma cannot unwind quickly.

The Q3 result is the recurring-mix thesis playing out: the highest-margin segment (CrossLab, 34.3% op margin) grew to $786M = 41.9% of revenue, driving the ~440 bps YoY GAAP gross-margin expansion. Agilent is also a direct GLP-1 supply-chain beneficiary — management disclosed GLP-1-related revenue +70% YoY (both the Biovectra oligo CDMO and the analytical lab businesses), with biopharma ex-CDOM +9%.

• FY2025 revenue of $6,948M vs. $6,510M in FY2024, with FY2025 gross margin 52.43% and operating margin 21.29% on StockAnalysis’s financials page.
• Agilent’s May 27, 2026 Q2 FY2026 earnings release raised full-year FY2026 revenue guidance to $7.39B-$7.49B and non-GAAP EPS to $6.00-$6.10.
• Management said the quarter reflected "healthy underlying demand" and the increasing impact of Ignite Operating System; the release also highlighted the new 9500 ICP-MS platform.
• Social/market commentary after the release was broadly positive on the beat and raised guidance, but later X commentary flagged valuation as fair-to-rich and noted limited near-term catalysts.
• SEC companyfacts for FY2025 show $6.948B revenue, $3.305B cost of goods and services sold, $3.643B gross profit, and $1.479B operating income.
• SEC companyfacts for FY2026 Q2 YTD (ended 2026-04-30) show $3.633B revenue vs. $3.349B a year earlier (+8.5%), $1.697B cost of goods and services sold, $1.936B gross profit, and $752M operating income.
• Agilent’s FY2025 10-K says the software business is tied to the installed base and new instrument sales; the chromatography business can be configured and stepwise upgraded into analytical and preparative workflow solutions.
• SEC submissions JSON shows no new Agilent filing after 2026-07-01, so the latest management update remains the Q2 FY2026 release from May.
• 10-K language ties Agilent software to the installed base and says LC systems can be stepwise upgraded, which makes replacement slow and method-heavy rather than plug-and-play.
• The Q2 FY2026 EX-99.1 release said strength reflected "healthy underlying demand," the increasing impact of Ignite Operating System, replacement-cycle momentum, and the new 9500 ICP-MS platform.
• Segment data in the Q2 release showed Life Sciences and Diagnostics Markets revenue of $732M (+12% YoY), Agilent CrossLab revenue of $759M (+6% YoY) with 55.5% gross margin, and Applied Markets revenue of $344M (+14% YoY).
• SEC companyfacts show FY2026 Q2 YTD revenue of $3.633B, gross profit of $1.936B (53.3% gross margin), and operating income of $752M (20.7% operating margin).

Public parameter table

On the FY2026 revenue guide midpoint ($7.44B), every 100 bps of gross margin equals about $74.4M of gross profit. A 200 bps margin slip would therefore cost about $148.8M of gross profit, roughly 10% of FY2025 operating income. Sensitivity-wise, a 2% revenue hit at that guide midpoint is also about $148.8M. That is the real economic constraint: once a lab standardizes on Agilent methods, software, and consumables, the company only has to protect a small fraction of the base to keep earnings power intact.

• The 2026-04-30 10-Q says Agilent CrossLab is "well positioned to continue its success ... by supporting a growing installed base of instruments" and that digital/remote capabilities improve service quality.
• The 2026-05-27 EX-99.1 release raised FY2026 revenue guidance to $7.39B-$7.49B and non-GAAP EPS to $6.00-$6.10.
• Companyfacts show FY2026 six-month revenue of $3.633B versus $3.349B a year earlier (+8.5%).
• The same release cites the new 9500 ICP-MS platform as an innovation driver.

\[

\text{5-yr GP} = 100{,}000 \times 0.50 + 0.90 \times 5 \times 27{,}000 \times 0.60

\]

\[

= 50{,}000 + 0.90 \times 135{,}000 \times 0.60

\]

\[

= 50{,}000 + 72{,}900 = \$122{,}900

\]

\[

\Delta Revenue = 6,510 \times [(0.35 \times -0.10) + (0.65 \times 0.05)]

\]

\[

\Delta Revenue = 6,510 \times [-0.035 + 0.0325] = 6,510 \times -0.0025 = -16.3\text{ million}

\]